Low-intensity focused ultrasound neuromodulation for drug-resistant epilepsy: A randomized, sham-controlled crossover trial

IF 5.6 1区 医学 Q1 CLINICAL NEUROLOGY
Epilepsia Pub Date : 2026-11-14 Epub Date: 2026-08-01 DOI:10.1002/epi.70404
Chien-Chen Chou, Yen-Cheng Shih, Yi-Hsiu Chen, Po-Tso Lin, Chun-Fu Lin, Po-Chun Chu, Hao-Li Liu, Cheng-Chia Lee, Hsiang-Yu Yu
{"title":"Low-intensity focused ultrasound neuromodulation for drug-resistant epilepsy: A randomized, sham-controlled crossover trial","authors":"Chien-Chen Chou,&nbsp;Yen-Cheng Shih,&nbsp;Yi-Hsiu Chen,&nbsp;Po-Tso Lin,&nbsp;Chun-Fu Lin,&nbsp;Po-Chun Chu,&nbsp;Hao-Li Liu,&nbsp;Cheng-Chia Lee,&nbsp;Hsiang-Yu Yu","doi":"10.1002/epi.70404","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study was undertaken to evaluate the safety, feasibility, and efficacy of low-intensity focused ultrasound (LIFU) as a noninvasive neuromodulation technique in patients with drug-resistant epilepsy (DRE).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this pilot, single-blind, randomized sham-controlled crossover trial, 12 patients with DRE underwent both LIFU and sham stimulation in a randomized sequence, targeting the seizure onset zone (SOZ), each followed by a 4-week observation period. Seizure frequency was analyzed as proportional change from baseline using linear mixed-effects models. An open-label extension phase evaluated longitudinal seizure outcomes following LIFU. Safety assessments included neurological examinations, magnetic resonance imaging (MRI), and neuropsychological and quality of life (QOL) measures.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During the crossover phase, LIFU did not significantly reduce seizure frequency compared with sham (estimate = .49, 95% confidence interval [CI] = −.04 to 1.01, <i>p</i> = .068). No period or sequence effects were observed. Conversely, during the open-label extension phase, seizure frequency demonstrated a significant longitudinal reduction following LIFU (β = −14.0 percentage points per month, 95% CI = −22.2 to −5.8, <i>p</i> = .001). Post-LIFU MRI showed no structural lesions. No significant changes were observed in anxiety, depression, or QOL scores. There were only transient mild-to-moderate adverse events reported, without serious complications.</p>\n </section>\n \n <section>\n \n <h3> Significance</h3>\n \n <p>LIFU neuromodulation targeting the SOZ is safe and well tolerated. Although the primary crossover analysis did not demonstrate a statistically significant antiseizure effect, delayed seizure reduction during the extended follow-up suggests potential sustained neuromodulatory effects. Larger parallel-group trials with longer observation periods are warranted.</p>\n </section>\n </div>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":"67 11","pages":"5715-5728"},"PeriodicalIF":5.6000,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/epi.70404","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/epi.70404","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

This study was undertaken to evaluate the safety, feasibility, and efficacy of low-intensity focused ultrasound (LIFU) as a noninvasive neuromodulation technique in patients with drug-resistant epilepsy (DRE).

Methods

In this pilot, single-blind, randomized sham-controlled crossover trial, 12 patients with DRE underwent both LIFU and sham stimulation in a randomized sequence, targeting the seizure onset zone (SOZ), each followed by a 4-week observation period. Seizure frequency was analyzed as proportional change from baseline using linear mixed-effects models. An open-label extension phase evaluated longitudinal seizure outcomes following LIFU. Safety assessments included neurological examinations, magnetic resonance imaging (MRI), and neuropsychological and quality of life (QOL) measures.

Results

During the crossover phase, LIFU did not significantly reduce seizure frequency compared with sham (estimate = .49, 95% confidence interval [CI] = −.04 to 1.01, p = .068). No period or sequence effects were observed. Conversely, during the open-label extension phase, seizure frequency demonstrated a significant longitudinal reduction following LIFU (β = −14.0 percentage points per month, 95% CI = −22.2 to −5.8, p = .001). Post-LIFU MRI showed no structural lesions. No significant changes were observed in anxiety, depression, or QOL scores. There were only transient mild-to-moderate adverse events reported, without serious complications.

Significance

LIFU neuromodulation targeting the SOZ is safe and well tolerated. Although the primary crossover analysis did not demonstrate a statistically significant antiseizure effect, delayed seizure reduction during the extended follow-up suggests potential sustained neuromodulatory effects. Larger parallel-group trials with longer observation periods are warranted.

Abstract Image

低强度聚焦超声神经调节治疗耐药癫痫:一项随机、假对照交叉试验。
目的:评价低强度聚焦超声(LIFU)作为一种无创神经调节技术在耐药癫痫(DRE)患者中的安全性、可行性和有效性。方法:本试验采用单盲、随机、假对照交叉试验,12例DRE患者按随机顺序分别对癫痫发作区(SOZ)进行LIFU和假刺激,各进行4周观察期。使用线性混合效应模型分析癫痫发作频率与基线的比例变化。开放标签延长期评估LIFU后纵向癫痫发作结果。安全性评估包括神经学检查、磁共振成像(MRI)、神经心理学和生活质量(QOL)测量。结果:在交叉期,与假手术相比,LIFU没有显著降低癫痫发作频率(估计=。49, 95%置信区间[CI] = - 0.04 ~ 1.01, p = 0.068)。没有观察到周期或序列效应。相反,在开放标签扩展阶段,癫痫发作频率在LIFU后显示出显著的纵向降低(β =每月-14.0个百分点,95% CI = -22.2至-5.8,p = .001)。lifu后MRI未见结构性病变。在焦虑、抑郁或生活质量评分方面未观察到显著变化。仅报告了短暂的轻至中度不良事件,无严重并发症。意义:针对SOZ的LIFU神经调节是安全且耐受性良好的。虽然最初的交叉分析没有显示统计学上显著的抗癫痫效果,但延长随访期间延迟发作减少表明潜在的持续神经调节作用。更大的平行组试验和更长的观察期是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia
Epilepsia 医学-临床神经学
CiteScore
10.90
自引率
10.70%
发文量
319
审稿时长
2-4 weeks
期刊介绍: Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书